Key result
An FDA advisory committee unanimously agreed that the approved COX-2 inhibitors (rofecoxib, celecoxib, and valdecoxib) significantly increase users' risk of cardiovascular events.
Why the study?
Do COX-2 inhibitors increase the risk of cardiovascular events in patients with pain and arthritis?
Do COX-2 inhibitors increase the risk of cardiovascular events in patients with pain and arthritis?
No takes yet. Share an insight, caveat, or question.
An FDA advisory committee unanimously agreed that COX-2 inhibitors pose serious cardiovascular hazards, including increased risk of heart attacks and strokes.
Susan Okie (2005) conducted an editorial in Pain and arthritis. COX-2 inhibitors (rofecoxib, celecoxib, valdecoxib) was evaluated on Cardiovascular events, including heart attacks and strokes. An FDA advisory committee unanimously agreed that the approved COX-2 inhibitors (rofecoxib, celecoxib, and valdecoxib) significantly increase users' risk of cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: